Motiv8 Investments’s Altimmune ALT Stock Holding History

Motiv8 Investments’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$0	Buy	+67	New	+$292	﹤0.01%	908

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Motiv8 Investments's ALT Position: Q4 2025 in Review

Motiv8 Investments opened a new position in Altimmune (ALT) in Q4 2025: 67 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #908 among its holdings.

181 funds tracked by Wall St. Rank hold ALT as of Q4 2025.

Motiv8 Investments held 67 shares of Altimmune worth $0 as of Q4 2025.
Altimmune was a new Motiv8 Investments position in Q4 2025.
Altimmune made up ﹤0.01% of Motiv8 Investments's portfolio in Q4 2025, its #908 holding.
181 funds tracked by Wall St. Rank held Altimmune as of Q4 2025.

Based on Motiv8 Investments's 13F filing for Q4 2025, filed 13 Feb 2026.